TM30339

Target: Y4
Status: Phase I

TM30339 works through the Y4 receptor like the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties over PP. Thus, TM30339 mimics a natural satiety signal from the gastrointestinal tract involved in the regulation of food intake in man. In pre-clinical studies in diet-induced obese mice, the Y4 receptor selective TM30339 was highly efficacious with respect to long term body weight reduction.

TM30339 entered into clinical Phase I/II study in the beginning of 2007.

The Target

The Y2 and the Y4 receptors have both previously been validated in man as independent appetite suppressive drug targets through the use of the natural hormones. 7TM Pharma’s Y receptor peptides have been developed as a first-in-class compounds, using the company’s structure-based drug discovery approach as well as world-leading expertise within the Y receptor field, i.e. detailed structural insight and knowledge about drug-receptor interactions.